Physician profile
Thomas David Catron
NPI 1851787931
$2,977.72
in general payments reported to CMS, 2019-2025
28 companies · $461 in 2025
The $461 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $22.25 · 2021: $591 · 2022: $1,096 · 2023: $467 · 2024: $176 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086 · Education: $18.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.60 |
| Education | $18.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,143.16 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $618.01 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $265.08 | 2021-2022 | |
| Qol Medical, LLC | $108.14 | 2021-2022 | |
| Janssen Biotech, INC. | $102.37 | 2020-2022 | |
| Madrigal Pharmaceuticals | $85.82 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $79.34 | 2022-2023 | Ibsrela |
| Merck Sharp & Dohme LLC | $54.33 | 2021-2022 | |
| Celgene Corporation | $48.45 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $47.62 | 2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $45.23 | 2021-2022 | |
| Braintree Laboratories, INC. | $40.12 | 2025 | Suflave |
| Phathom Pharmaceuticals, INC. | $34.95 | 2024 | Voquezna |
| Celltrion USA INC. | $33.40 | 2024-2025 | Zymfentra, Vegzelma |
| Pfizer INC. | $31.52 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $30.50 | 2024-2025 | Hadlima |
| Regeneron Healthcare Solutions, INC. | $22.55 | 2022 | |
| Novo Nordisk INC | $22.51 | 2025 | Wegovy |
| Intra-Sana Laboratories | $21.15 | 2022 | |
| Lucid Diagnostics INC. | $19.47 | 2023 | |
| Intercept Pharmaceuticals, INC. | $18.86 | 2019 | |
| Lilly USA, LLC | $18.23 | 2025 | Omvoh |
| Boston Scientific Corporation | $16.22 | 2022 | |
| Aimmune Therapeutics, INC. | $16.18 | 2025 | Zenpep |
| W. L. Gore & Associates, INC. | $15.50 | 2023 | Gore Cardioform Septal Occluder |
| Bayer Healthcare Pharmaceuticals INC. | $14.15 | 2019 | |
| Echosens North America, INC. | $12.50 | 2025 | Fibroscan |
| Alexion Pharmaceuticals, INC. | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Catron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.